PNC-27 is a laboratory-designed peptide studied only in cell cultures and animal models, never in humans. It combines a fragment of the p53 tumor-suppressor protein with a cell-penetrating sequence called penetratin, and is engineered to bind a protein called HDM-2 on the surface of cancer cell membranes, punching pores in them and killing the cells through necrosis rather than the more common process of programmed cell death.
Research snapshot
| Peptide category | Synthetic p53-derived / penetratin chimeric peptide (preclinical research compound) |
| Primary research interest | Selective cancer-cell killing via HDM-2 binding at the cancer-cell plasma membrane |
| Highest available evidence | Published in vitro (cell-culture) research and limited animal (xenograft) research; no published human data |
| Human research available | No — PNC-27 has never been tested in humans |
| Development status | Preclinical academic research compound; not in any known clinical development pipeline |
| Regulatory status | Not approved anywhere; no known IND or registered clinical trials |
| Last reviewed | September 27, 2026 |
Technical identity
| Primary name | PNC-27 |
| Alternative names | None widely used; related compound PNC-28 is a distinct sequence from the same research program |
| Peptide sequence | H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH |
| Amino-acid length | 32 residues |
| Molecular formula | Not reliably established from authoritative chemical databases |
| Molecular weight | Not reliably established from authoritative chemical databases |
| CAS Registry Number | No verified CAS Registry Number could be identified from authoritative chemical databases |
| PubChem CID | No verified PubChem CID could be identified from authoritative chemical databases |
| UNII | Not established |
| DrugBank ID | Not established |
| Chemical modifications | Fusion of a p53 HDM-2-binding fragment with the penetratin cell-penetrating peptide sequence |
| Peptide class | p53-derived / penetratin chimeric peptide |
| Primary biological target | HDM-2 (MDM2 homolog) presented on the plasma membrane of cancer cells |
| Developer or originator | Academic research program (Roswell Park Cancer Institute-affiliated research) |
| Development status | Preclinical only |
What it is
PNC-27 is a synthetic, chimeric 32-residue peptide (reported sequence: H-Pro-Pro-Leu-Ser-Gln-Glu-Thr-Phe-Ser-Asp-Leu-Trp-Lys-Leu-Leu-Lys-Lys-Trp-Lys-Met-Arg-Arg-Asn-Gln-Phe-Trp-Val-Lys-Val-Gln-Arg-Gly-OH) built from two functional parts: a segment corresponding to the HDM-2-binding region of the p53 tumor-suppressor protein, and the “penetratin” sequence, a well-known cell-penetrating peptide originally derived from the Drosophila Antennapedia homeodomain. It was designed and characterized by researchers (notably groups associated with Kalinski, Sarafraz-Yazdi, and Pincus at New York Medical College) beginning in the mid-2000s, building on earlier work with a related peptide, PNC-28.
The rationale behind PNC-27 rests on the observation that HDM-2 (the human analog of murine MDM2, a natural inhibitor of p53) is overexpressed not just inside the nucleus of many cancer cells but also on their outer plasma membrane, a feature that appears far less common in normal, non-cancerous cells. PNC-27 was designed to exploit this by binding membrane-associated HDM-2 directly, rather than by working through the intracellular p53 pathway the way many other p53-related cancer therapeutics attempt to. This gives it a proposed mechanism of selective toxicity toward cancer cells that display surface HDM-2, largely sparing normal cells that lack it.
PNC-27 is exclusively a preclinical research compound. It has been evaluated in numerous cancer cell lines (including pancreatic, breast, melanoma, and leukemia lines) and in some animal tumor models, but it has not entered human clinical trials, has no registered clinical development program identified in this review, and is not an approved or investigational new drug in any regulatory sense. It should be understood strictly as an early-stage academic research tool rather than a drug candidate with clinical-stage evidence.
How does it work?
Plain-English explanation
Many cancer cells display a protein called HDM-2 on their outer surface, something healthy cells mostly do not do. PNC-27 is built to latch onto that surface protein and then punch a hole in the cancer cell’s outer membrane, causing the cell to burst and die quickly (necrosis) rather than dying through the body’s normal, more controlled cell-death process (apoptosis). Because it targets a feature specific to the cancer cell’s outer membrane, researchers hope it could kill tumor cells while leaving normal cells largely undamaged.
Technical explanation
Structural and biochemical studies indicate that the C-terminal residues of PNC-27 (roughly corresponding to the p53-derived segment) fold into a conformation resembling the native p53-HDM-2 binding interface, allowing PNC-27 to bind membrane-associated HDM-2 in cancer cells. Rather than being internalized and degraded, the peptide is reported to adopt an alpha-helix-loop-alpha-helix structure that inserts into and remains within the cancer cell plasma membrane, where it forms pores, causing membranolysis and necrotic cell death. This is described as distinct from classical apoptotic pathways and appears to depend specifically on the target cell expressing HDM-2 in its plasma membrane, since untransformed cell lines lacking surface HDM-2 have shown much lower sensitivity in reported experiments. Reported in vitro effective concentrations in these studies have ranged roughly from about 10 micrograms/mL to over 1 mg/mL depending on assay and exposure time, figures that come from laboratory cell-culture work and do not translate directly to any human dose.
Potential benefits and research applications
Selective cancer cell killing (preclinical)
What is being investigated: whether PNC-27 can selectively kill cancer cells that express surface HDM-2 while sparing normal cells. How the effect might occur: membrane-pore formation following HDM-2 binding, as described above. Evidence: cell-culture studies across several cancer cell lines (pancreatic, breast, melanoma, leukemia) reporting cytotoxic and necrotic effects, plus some tumor-regression findings referenced from earlier work in nude mouse models. Strength: Tier 3-4 (animal and laboratory/mechanistic evidence only; no human data). Limitation: no human trials exist, dosing and pharmacokinetics in a whole living human body are unknown, and translation from cell culture and mouse models to human efficacy and safety cannot be assumed.
p53-independent tumor targeting
What is being investigated: whether PNC-27’s membrane-based mechanism can kill cancer cells regardless of whether their own intracellular p53 gene is mutated or functional, a potential advantage since many tumors have lost normal p53 function. How the effect might occur: because PNC-27 acts at the cell membrane on HDM-2 rather than requiring intracellular p53 signaling, it is proposed to work even in p53-mutant or p53-null cancer cells. Evidence: reported in laboratory cell-line studies. Strength: Tier 4, mechanistic/laboratory only. Limitation: this remains a hypothesis supported by in vitro observations, not confirmed in any human or advanced in vivo efficacy setting.
What dosage information circulates?
Figures in this section summarize amounts and schedules reported in published research or circulating online. Their inclusion documents what is reported and does not establish that a regimen is verified, safe, effective, or appropriate.
| Reported use or research objective | Route reported | Amount reported | Frequency reported | Reported duration | Evidence or source category |
|---|---|---|---|---|---|
| Selective cancer-cell killing (in vitro) | Direct cell-culture exposure | Roughly 10 mcg/mL to 1 mg/mL; commonly cited around 50 mcg/mL | Single exposure | 15 minutes to several hours | Published laboratory (cell-culture) research |
| Tumor regression (animal xenograft) | Not independently confirmed against full primary-text methods | Not independently confirmed | Not independently confirmed | Not independently confirmed | Published animal research (referenced from related early PNC-27/PNC-28 work; schedule not independently verified during this review) |
| Community or self-directed use | Reported as injectable by some vendor and forum sources | Widely repeated online, but its original source could not be verified | Not consistently reported | Not consistently reported | Vendor / community reported — PNC-27 has never been tested in a human, so any circulating human-use figures are unverified extrapolations |
Amounts studied in human research
No established or reliably sourced dosing information was identified. PNC-27 has not been studied in humans; there is no human clinical dosing data of any kind.
Amounts studied in animal research
Published laboratory reports describe in vitro exposure concentrations for cultured cancer cells in roughly the 10 micrograms/mL to 1 mg/mL range across different assay types (with a commonly cited standard treatment concentration around 50 micrograms/mL for periods of 15 minutes to several hours), and earlier referenced work describes tumor regression in nude mouse xenograft models, though a fully detailed in vivo dosing schedule (mg/kg, route, frequency) was not confirmed against a primary source in this review and should be checked directly in the original animal-model publications before being cited as an established figure (published animal/laboratory research; source category noted as partially unconfirmed for the in vivo dose specifically).
Practitioner and community-reported protocols
PNC-27 is sold by some research-chemical and peptide vendors and discussed in online communities with informally suggested self-administration protocols. These figures are widely repeated online, but their original source could not be verified, and given that PNC-27 has never been tested in a living human being in any clinical setting, no such community-reported protocol should be interpreted as having any established safety or efficacy basis (community/vendor reported, origin unclear).
What circulates E5
PNC-27 is sold by some research-chemical and peptide vendors and discussed in online communities with informally suggested self-administration protocols. These figures are widely repeated online, but their original source could not be verified.
Given that PNC-27 has never been tested in a living human being in any clinical setting, no such community-reported protocol should be interpreted as having any established safety or efficacy basis, and no specific amount was consistent enough across sources to responsibly tabulate here.
Recorded as an observation about what is published elsewhere. No figure here is a dose, a protocol, or a recommendation, and nothing in this section is evidence that any amount is safe or effective.
Side effects, risks, and limitations
Because PNC-27 has no human trial history, there is no characterized human side-effect profile, no known safe dose range in humans, and no data on pharmacokinetics, immunogenicity, or long-term effects in a living person. Its proposed mechanism, inducing necrosis by forming pores in cell membranes, is a generally more inflammatory and less controlled form of cell death than apoptosis, which raises theoretical concerns about off-target tissue damage or inflammatory responses if HDM-2 is expressed, even at low levels, on the surface of some non-cancerous cells; the degree of true selectivity in a whole organism is not established. As an unapproved research chemical, any material sold as “PNC-27” also carries the general risks associated with unregulated peptides: uncertain purity, incorrect concentration, contamination, and lack of sterility assurance. Self-administration of a compound with zero human safety data carries risks that cannot be quantified from the existing preclinical literature.
Regulatory and developmental status
PNC-27 is an academic preclinical research compound. It is not approved by the FDA or any other regulatory body for any use, has no identified registered clinical trial (interventional human study) in trial registries reviewed for this entry, and has not publicly progressed to an Investigational New Drug (IND) stage that could be confirmed from the sources available. It should be classified strictly as an experimental laboratory tool rather than a drug in development toward approval. Status verified as of the date below based on the absence of any identified clinical-stage development.
Frequently asked questions
What is PNC-27?
It is a synthetic, laboratory-designed peptide combining a p53-derived HDM-2-binding fragment with the penetratin cell-penetrating sequence, studied preclinically for its ability to selectively kill cancer cells that express HDM-2 on their outer membrane.
Has PNC-27 been tested in humans?
No. All available evidence comes from cell-culture (in vitro) studies and some animal tumor models. There are no published human clinical trials.
How does PNC-27 kill cancer cells?
It binds HDM-2 protein present on the outer surface of many cancer cells and is reported to form pores in the cell membrane, causing the cell to die by necrosis rather than by the more typical apoptosis pathway.
What dosage has been studied?
No established or reliably sourced human dosing information was identified. Reported figures are laboratory cell-culture concentrations (roughly 10 micrograms/mL to 1 mg/mL) or animal-model amounts, which cannot be translated into a human dose.
Is PNC-27 the same as PNC-28?
No, though they are related compounds from the same research program; PNC-28 is a separate peptide sharing the penetratin cell-penetrating sequence, studied in some of the same laboratories for related but distinct anticancer mechanisms.
Is PNC-27 approved or in clinical trials?
No. It is an unapproved, preclinical-only research compound with no identified registered human trial.
Is it safe to use?
This has not been established in humans at all. With zero human safety data, no dose can be considered established as safe.
What remains unknown?
Whether PNC-27’s cancer-cell selectivity seen in cell culture and limited animal models would hold up in a living human, what a safe or effective human dose might be, and whether the necrosis-inducing mechanism would produce unacceptable toxicity in vivo, are all unresolved questions with no clinical data to answer them.
Bottom line
PNC-27 is a scientifically interesting, mechanistically well-described preclinical research peptide with a genuinely novel proposed anticancer mechanism (membrane-level HDM-2 binding and pore formation leading to necrosis), but it remains entirely unproven in humans. All available evidence is at the cell-culture and limited-animal-model level. There is no established human dosing information, no clinical trial history, and no regulatory approval of any kind. It should be treated strictly as a laboratory research tool, not as a therapeutic option.